APRE fundamentals
Key facts
About
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−2,600.0%
−2,100.0%
−1,600.0%
−1,100.0%
−600.0%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−4.50 M
−3.00 M
−1.50 M
0.00
1.50 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
No dividends
APRE has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company